Return to Home Ensuring Appropriate Use Educating Patients Resources for Healthcare Professionals

SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII)
SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII)
SUBUTEX® (buprenorphine) Sublingual Tablet (CIII)

Educating Patients

The SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet Medication Guides are a core component of the REMS program. Each respective Medication Guide contains important information about the product, including proper administration, potential adverse events, and other precautions.

You should review the medication guide with patients for whom you prescribe SUBOXONE Film, SUBOXONE Tablet, or SUBUTEX Tablet to ensure that they understand the proper use and safety precautions associated with these products. If you require additional copies of the medication guide, you can request them through your Clinical Specialist or by calling 1-866-463-4846.

Additionally, Medication Guides are provided to pharmacies that order and dispense SUBOXONE Film, SUBOXONE Tablet or SUBUTEX Tablet with reminders that they should provide the correct Medication Guide with every prescription.

Communicate the following messages to patients about the serious risks of accidental overdose, misuse, and abuse:

  • Instruct patients to keep these products in a secure place, out of the sight and reach of all others, especially children. Accidental or deliberate ingestion by a child may cause respiratory depression that can result in death. If a child is exposed to one of these products, medical attention should be sought immediately.
  • Warn patients that it is extremely dangerous to self-administer non-prescribed benzodiazepines or other central nervous system (CNS) depressants (including alcohol) while taking these products. Caution patients prescribed benzodiazepines or other CNS depressants to use them only as directed by their prescriber.
  • Instruct patients never to give these products to anyone else, even if he or she has the same signs and symptoms. They may cause harm or death.
  • Advise patients that these products contain an opioid that can be a target for people who abuse prescription medications or street drugs.
  • Advise patients that selling or giving away these products is against the law.
  • Discuss with patients the importance of having access to naloxone.
  • Use the contents of each drug product's Medication Guide, in its entirety, with each patient to review the information noted above, including side effects and what to do if a patient has them. The Medication Guide will be dispensed with each prescription for a buprenorphine-containing transmucosal product.
  • Encourage patients to seek psychosocial counseling and support for safe and effective treatment.

Additional information about safe use conditions and patient monitoring can be found in the Prescriber Brochure and in the warning and precautions sections of the product-specific Prescribing Information.

You are leaving

Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Clicking on "Continue" will take you to a website that is outside the control of Indivior Inc. You are solely responsible for your interactions with such websites.

Continue Cancel button

As always, the information you give us will not be sold or shared with anyone. Please see our privacy policy for more information.

The requested information is provided in Portable Document Format (PDF). To view and print this document you'll need to install a copy of the free Adobe® Acrobat® Reader®. If you already have Adobe Acrobat Reader installed click "VIEW PDF" below. If you need the Acrobat Reader you can download it from the Adobe Acrobat Reader Download page.

View PDFCancel button

Don't show me this message again.